Home » BerGenBio Doses First COVID-19 Patient with Bemcentinib in ACCORD Trial
BerGenBio Doses First COVID-19 Patient with Bemcentinib in ACCORD Trial
June 3, 2020
BerGenBio has announced that the first COVID-19 patient was dosed with bemcentinib in a phase 2 trial to evaluate the drug as a potential treatment.
The study will assess the oral kinase inhibitor in addition to standard of care. It will recruit 120 hospitalized COVID-19 patients, giving 60 participants bemcentinib in addition to the standard of care, while the others will receive only the standard of care.
Bemcentinib is the first candidate to be tested as a part of the UK’s Accelerating COVID-19 Research & Development (ACCORD) platform trial of multiple early-stage COVID-19 treatments.
Upcoming Events
-
21Oct